These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3195200)

  • 1. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
    Ishida H; Saiki I; Saito S; Hasegawa A; Kiso M; Azuma I
    Vaccine; 1988 Oct; 6(5):440-4. PubMed ID: 3195200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical combination of 6-deoxy-6-mycoloylamino-alpha,alpha-trehalose and N-acetyl-6-O-(aminoacyl)muramoyl dipeptide.
    Ishida H; Ogawa Y; Imai Y; Kiso M; Hasegawa A; Sakurai T; Azuma I
    Carbohydr Res; 1989 Dec; 194():199-208. PubMed ID: 2620300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.
    McLaughlin CA; Schwartzman SM; Horner BL; Jones GH; Moffatt JG; Nestor JJ; Tegg D
    Science; 1980 Apr; 208(4442):415-6. PubMed ID: 7189295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant activities of synthetic lipid A subunit analogues and its conjugates with muramyl dipeptide derivatives.
    Maeda H; Saiki I; Ishida H; Kiso M; Hasegawa A; Azuma I
    Vaccine; 1989 Jun; 7(3):275-81. PubMed ID: 2675486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
    Shimizu T; Iwamoto Y; Yanagihara Y; Ikeda K; Achiwa K
    Int J Immunopharmacol; 1992 Nov; 14(8):1415-20. PubMed ID: 1464473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
    Azuma I
    Vaccine; 1992; 10(14):1000-6. PubMed ID: 1471423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a synthetic adjuvant for inducing anti-tumour immunity.
    Kataoka T; Kinomoto M; Takegawa M; Tokunaga T
    Vaccine; 1991 May; 9(5):300-2. PubMed ID: 1872013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial cell surface biological response modifiers and their synthetic counterparts.
    Kotani S
    Adv Exp Med Biol; 1992; 319():145-64. PubMed ID: 1414590
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A.
    Tsujimoto M; Kotani S; Okunaga T; Kubo T; Takada H; Kubo T; Shiba T; Kusumoto S; Takahashi T; Goto Y
    Vaccine; 1989 Feb; 7(1):39-48. PubMed ID: 2718605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
    Azuma I; Sugimura K; Yamawaki M; Uemiya M; Kusumoto S; Okada S; Shiba T; Yamamura Y
    Infect Immun; 1978 Jun; 20(3):600-7. PubMed ID: 97234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a nontoxic lipid A fraction containing tumor regression activity.
    Takayama K; Ribi E; Cantrell JL
    Cancer Res; 1981 Jul; 41(7):2654-7. PubMed ID: 7018667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
    Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
    Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
    Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
    Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of line-10 hepatocarcinoma with synthetic quinonyl muramyl dipeptide in strain-2 guinea pigs.
    Tanio Y; Souma H; Tokushima Y; Yamamura Y; Azuma I
    Gan; 1983 Apr; 74(2):192-5. PubMed ID: 6862142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brucella abortus vaccines: comparison of protection provided by immunopotentiated 45/20 bacterins and live strain 19 vaccine in guinea pigs.
    Woodard LF; Toone NM; Jasman RL
    Am J Vet Res; 1981 Nov; 42(11):1959-62. PubMed ID: 6802042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.